Galecto is a clinical-stage biotechnology company focused on developing small molecule therapeutics for fibrosis, cancer, inflammation, and related diseases. The company's lead program, GB1211, is an oral small molecule inhibitor of galectin-3 being evaluated for multiple oncology and liver disease indications. A second program, GB3226, is a preclinical dual inhibitor targeting ENL-YEATS and FLT3 proteins. Both candidates represent Galecto's approach to addressing galectin-mediated disease pathways.
As a clinical-stage company, Galecto does not generate product revenues and operates primarily through research and development activities. The company is headquartered in Copenhagen, Denmark, where it was founded in 2011, and is incorporated in Delaware. Galecto maintains a small operational footprint with five full-time employees, typical of clinical-stage biotech companies in early development phases. The company is listed on Nasdaq, providing public market funding access for its development programs.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-18.53 | $-18.53 | -1186.8% | |
| 2023 | $-1.44 | $-1.44 | +40.7% | |
| 2022 | $-2.43 | $-2.43 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |